Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MeiHua Holdings Group Co.,Ltd (600873.SS)
Langfang, CN
MeiHua Holdings Group Co.,Ltd, a company established in Langfang, China, in 2002, specializes in delivering comprehensive amino acid-based nutrition and health solutions. Its diverse product portfolio caters to multiple industries. For the food sector, MeiHua manufactures an array of additives such as sodium glutamate, natamycin, disodium 5'-ribonucleotide, disodium inosinate, xanthan gum, pullulan, and trehalose. It also produces essential condiments like monosodium glutamate (MSG). The company provides various amino acids designed for animal feed, including valine, L-lysine sulphate and HCL, L-threonine, and L-tryptophane. Additionally, its feedstuff offerings comprise corn gluten meal, corn husk powder, corn fiber feed, and specialized MSG residue. In the pharmaceutical domain, MeiHua supplies vital amino acids such as L-glutamine, L-leucine, L-isoleucine, L-valine, branched-chain amino acids (BCAA), L-proline, inosine, vernine, and adenosine. Beyond these core areas, MeiHua's extensive product line also encompasses colloids, a variety of capsules (enteric, cellulose, gelatin, and pullulan types), and agricultural fertilizers, particularly soil conditioners.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.69% | -1.57% | -5.04% | -17.80% | -7.10% | -7.01% | -10.11% | +3.40% | +47.65% | +38.73% | +454.12% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-3.7% Q1'26: -4.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+24.5% ★ Q1'26: -88.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+5.8% Q1'26: -27.8% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+10.8% ★ Q1'26: +2.2% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+13.9% ★ Q1'26: +2.1% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-3.8% ★ Q1'26: -0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.43× ★ Q1'26: 11.25× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.85B
est: 11.85B (+0.0%)
|
11.09B
est: 11.89B (-6.7%)
|
11.13B
est: 11.85B (-6.1%)
|
12.65B
est: 12.51B (+1.1%)
|
14.55B
est: 13.61B (+7.0%)
|
17.05B
est: 16.88B (+1.0%)
|
23.06B
est: 23.75B (-2.9%)
|
27.94B
est: 29.00B (-3.7%)
|
27.76B
est: 26.82B (+3.5%)
|
25.07B
est: 27.35B (-8.3%)
|
24.15B
est: 25.52B (-5.4%)
|
27.90B
26.14B – 30.09B
+9.3% YoY
|
30.16B
26.52B – 33.45B
+8.1% YoY
|
31.14B
31.09B – 31.20B
+3.3% YoY
|
| EBITDA |
2.14B
est: 2.18B (-2.0%)
|
2.44B
est: 2.19B (+11.5%)
|
2.50B
est: 2.18B (+14.3%)
|
2.65B
est: 2.30B (+15.2%)
|
2.67B
est: 2.51B (+6.6%)
|
2.68B
est: 3.11B (-13.9%)
|
4.16B
est: 4.37B (-4.8%)
|
6.40B
est: 5.34B (+19.9%)
|
4.91B
est: 5.00B (-1.7%)
|
4.44B
est: 5.10B (-12.8%)
|
4.06B
est: 4.76B (-14.7%)
|
5.20B
4.87B – 5.61B
+9.3% YoY
|
5.62B
4.94B – 6.24B
+8.1% YoY
|
5.81B
5.80B – 5.82B
+3.3% YoY
|
| EBIT |
909.26M
est: 1.48B (-38.6%)
|
1.22B
est: 1.49B (-17.9%)
|
1.32B
est: 1.48B (-10.6%)
|
1.41B
est: 1.56B (-9.5%)
|
1.30B
est: 1.70B (-23.4%)
|
1.25B
est: 2.11B (-40.9%)
|
2.74B
est: 2.97B (-7.6%)
|
5.02B
est: 3.62B (+38.6%)
|
3.57B
est: 3.54B (+0.8%)
|
3.12B
est: 3.61B (-13.4%)
|
2.61B
est: 3.37B (-22.5%)
|
3.68B
3.45B – 3.97B
+9.3% YoY
|
3.98B
3.50B – 4.42B
+8.1% YoY
|
4.11B
4.10B – 4.12B
+3.3% YoY
|
| Net Income |
425.46M
est: 809.01M (-47.4%)
|
1.04B
est: 940.20M (+10.8%)
|
1.17B
est: 1.98B (-40.8%)
|
1.00B
est: 1.02B (-1.8%)
|
988.64M
est: 1.14B (-13.0%)
|
982.06M
est: 1.08B (-9.0%)
|
2.40B
est: 2.45B (-1.9%)
|
4.41B
est: 4.25B (+3.8%)
|
3.18B
est: 3.28B (-3.1%)
|
2.74B
est: 3.03B (-9.7%)
|
3.28B
est: 3.44B (-4.6%)
|
2.31B
1.97B – 2.51B
-32.7% YoY
|
2.82B
2.31B – 3.39B
+21.9% YoY
|
3.42B
2.80B – 3.71B
+21.4% YoY
|
| SGA |
1.36B
est: 601.20M (+125.6%)
|
1.37B
est: 603.13M (+127.1%)
|
1.29B
est: 601.28M (+114.1%)
|
1.47B
est: 634.27M (+131.3%)
|
1.71B
est: 690.11M (+147.6%)
|
851.75M
est: 855.99M (-0.5%)
|
1.17B
est: 1.20B (-3.1%)
|
1.45B
est: 1.47B (-1.3%)
|
1.34B
est: 1.36B (-1.9%)
|
1.32B
est: 1.39B (-4.8%)
|
1.22B
est: 1.30B (-5.7%)
|
1.42B
1.33B – 1.53B
+9.3% YoY
|
1.53B
1.35B – 1.70B
+8.1% YoY
|
1.58B
1.58B – 1.59B
+3.3% YoY
|
| EPS |
0.14
est: 0.28 (-49.5%)
|
0.34
est: 0.32 (+5.4%)
|
0.38
est: 0.68 (-44.1%)
|
0.32
est: 0.35 (-8.6%)
|
0.32
est: 0.39 (-17.9%)
|
0.32
est: 0.37 (-13.5%)
|
0.78
est: 0.84 (-7.1%)
|
1.44
est: 1.47 (-2.0%)
|
1.06
est: 1.11 (-4.7%)
|
0.94
est: 1.05 (-10.5%)
|
1.17
est: 1.23 (-4.5%)
|
0.77
0.70 – 0.89
-37.3% YoY
|
0.97
0.82 – 1.21
+26.5% YoY
|
1.16
1.00 – 1.32
+19.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.18% | 3.29M | 0.58% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.14% | 51.1K | 0.65% |
| 3 | Invesco FTSE Emerging Markets High Dividend Low Volatility UCITS ETF EMHD.L | 0.09% | 269.6K | 0.49% |
| 4 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.08% | 288.8K | 0.44% |
| 5 | HSBC MSCI China A UCITS ETF HMCT.L | 0.07% | 99.2K | 0.30% |
| 6 | iShares Emerging Markets Equity Factor ETF EMGF | 0.03% | 540.6K | 0.26% |
| 7 | Franklin FTSE China ETF FLCH | 0.01% | 31.4K | 0.19% |
| 8 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 165.7K | 0.19% |
| 9 | Franklin Emerging Market Core Dividend Tilt Index ETF DIEM | 0.01% | 4.0K | 0.19% |
| 10 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 12.6K | 0.58% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jun He | GM & Director | — | male |
| Lihong Wang | Chief Financial Officer | — | female |
| Xianfang Liu | Secretary of the Board of Directors | — | female |
| You Wang | Deputy General Manager | — | male |
| Yu Bo Liang | Deputy GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600873.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
